Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc. more
Time Frame | ARMP | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.94% | 0.67% | 0.49% |
1-Month Return | -8.94% | 0.26% | 5.96% |
3-Month Return | -10.83% | -6.21% | 9.35% |
6-Month Return | -22.18% | 1.69% | 14.4% |
1-Year Return | -21.32% | 11.41% | 32.23% |
3-Year Return | -52.44% | 12.87% | 33.15% |
5-Year Return | -50.46% | 48.89% | 95.23% |
10-Year Return | -99.81% | 109.26% | 191.11% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 31.00K | 823.00K | 4.47M | 5.51M | 4.53M | [{"date":"2019-12-31","value":0.56,"profit":true},{"date":"2020-12-31","value":14.94,"profit":true},{"date":"2021-12-31","value":81.23,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":82.23,"profit":true}] |
Cost of Revenue | 1.35M | 14.44M | 20.02M | 892.00K | 33.77M | [{"date":"2019-12-31","value":4,"profit":true},{"date":"2020-12-31","value":42.77,"profit":true},{"date":"2021-12-31","value":59.27,"profit":true},{"date":"2022-12-31","value":2.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (1.35M) | (13.62M) | (15.54M) | 4.62M | (29.24M) | [{"date":"2019-12-31","value":-29.27,"profit":false},{"date":"2020-12-31","value":-295.08,"profit":false},{"date":"2021-12-31","value":-336.68,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-633.47,"profit":false}] |
Gross Margin | (4358.06%) | (1655.04%) | (347.36%) | 83.81% | (645.64%) | [{"date":"2019-12-31","value":-5200.22,"profit":false},{"date":"2020-12-31","value":-1974.86,"profit":false},{"date":"2021-12-31","value":-414.49,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-770.4,"profit":false}] |
Operating Expenses | 19.09M | 21.59M | 23.82M | 36.95M | 11.65M | [{"date":"2019-12-31","value":51.67,"profit":true},{"date":"2020-12-31","value":58.43,"profit":true},{"date":"2021-12-31","value":64.48,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":31.53,"profit":true}] |
Operating Income | (19.75M) | (21.59M) | (23.82M) | (36.95M) | (40.89M) | [{"date":"2019-12-31","value":-1975200000,"profit":false},{"date":"2020-12-31","value":-2158700000,"profit":false},{"date":"2021-12-31","value":-2382200000,"profit":false},{"date":"2022-12-31","value":-3694600000,"profit":false},{"date":"2023-12-31","value":-4089000000,"profit":false}] |
Total Non-Operating Income/Expense | (562.00K) | (1.19M) | 608.00K | 58.00K | (29.21M) | [{"date":"2019-12-31","value":-92.43,"profit":false},{"date":"2020-12-31","value":-196.38,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":9.54,"profit":true},{"date":"2023-12-31","value":-4803.62,"profit":false}] |
Pre-Tax Income | (19.48M) | (22.18M) | (23.16M) | (36.92M) | (69.05M) | [{"date":"2019-12-31","value":-1947900000,"profit":false},{"date":"2020-12-31","value":-2218100000,"profit":false},{"date":"2021-12-31","value":-2315500000,"profit":false},{"date":"2022-12-31","value":-3691700000,"profit":false},{"date":"2023-12-31","value":-6904500000,"profit":false}] |
Income Taxes | (454.00K) | 634.00K | 64.00K | (29.00K) | - | [{"date":"2019-12-31","value":-71.61,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":10.09,"profit":true},{"date":"2022-12-31","value":-4.57,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (19.02M) | (22.82M) | (23.22M) | (36.89M) | - | [{"date":"2019-12-31","value":-1902500000,"profit":false},{"date":"2020-12-31","value":-2281500000,"profit":false},{"date":"2021-12-31","value":-2321900000,"profit":false},{"date":"2022-12-31","value":-3688800000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (19.48M) | (22.18M) | (23.16M) | (36.92M) | (59.51M) | [{"date":"2019-12-31","value":-1947900000,"profit":false},{"date":"2020-12-31","value":-2218100000,"profit":false},{"date":"2021-12-31","value":-2315500000,"profit":false},{"date":"2022-12-31","value":-3691700000,"profit":false},{"date":"2023-12-31","value":-5951200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (19.02M) | (22.82M) | (23.22M) | (36.89M) | (69.05M) | [{"date":"2019-12-31","value":-1902500000,"profit":false},{"date":"2020-12-31","value":-2281500000,"profit":false},{"date":"2021-12-31","value":-2321900000,"profit":false},{"date":"2022-12-31","value":-3688800000,"profit":false},{"date":"2023-12-31","value":-6904500000,"profit":false}] |
EPS (Diluted) | (3.31) | (1.42) | (0.97) | (1.09) | (1.80) | [{"date":"2019-12-31","value":-331,"profit":false},{"date":"2020-12-31","value":-142,"profit":false},{"date":"2021-12-31","value":-97,"profit":false},{"date":"2022-12-31","value":-109,"profit":false},{"date":"2023-12-31","value":-180,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ARMP | |
---|---|
Cash Ratio | 0.15 |
Current Ratio | 0.19 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ARMP | |
---|---|
ROA (LTM) | -25.09% |
ROE (LTM) | -3439.35% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ARMP | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.52 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.52 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ARMP | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 21.40 |
P/B | 4.06 |
Price/FCF | NM |
EV/R | 148.14 |
EV/Ebitda | NM |
Armata Pharmaceuticals Inc (ARMP) share price today is $2.14
Yes, Indians can buy shares of Armata Pharmaceuticals Inc (ARMP) on Vested. To buy Armata Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ARMP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Armata Pharmaceuticals Inc (ARMP) via the Vested app. You can start investing in Armata Pharmaceuticals Inc (ARMP) with a minimum investment of $1.
You can invest in shares of Armata Pharmaceuticals Inc (ARMP) via Vested in three simple steps:
The 52-week high price of Armata Pharmaceuticals Inc (ARMP) is $4.48. The 52-week low price of Armata Pharmaceuticals Inc (ARMP) is $1.98.
The price-to-earnings (P/E) ratio of Armata Pharmaceuticals Inc (ARMP) is
The price-to-book (P/B) ratio of Armata Pharmaceuticals Inc (ARMP) is 4.06
The dividend yield of Armata Pharmaceuticals Inc (ARMP) is 0.00%
The market capitalization of Armata Pharmaceuticals Inc (ARMP) is $79.60M
The stock symbol (or ticker) of Armata Pharmaceuticals Inc is ARMP